Invivyd (IVVD) Amortization of Deferred Charges (2022 - 2025)
Invivyd's (IVVD) quarterly Amortization of Deferred Charges came in at $286000.0 in Q4 2025, down 33.8% YoY from $432000.0 in Q4 2024, and up 1.42% on a QoQ basis from $282000.0 in Q3 2025.
Invivyd (IVVD) Amortization of Deferred Charges (2022 - 2025) Analysis & Trends
Invivyd (IVVD) has 4 years of Amortization of Deferred Charges data on file, last reported at $286000.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges fell 33.8% year-over-year to $286000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 17.91% YoY) and the FY2025 annual result came in at $1.4 million, down 17.91% from the prior year.
- Amortization of Deferred Charges improved to $286000.0 in Q4 2025, from $282000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $432000.0 in Q4 2024 to a low of $31000.0 in Q3 2022.
- A 4-year average of $310500.0 and a median of $381500.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges jumped 1154.84% — and 2025, when it sank 33.96%.
- Tracing IVVD's Amortization of Deferred Charges over 4 years: stood at $179000.0 in 2022, then surged by 121.23% to $396000.0 in 2023, then increased by 9.09% to $432000.0 in 2024, then tumbled by 33.8% to $286000.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at $286000.0 (Q4 2025), $282000.0 (Q3 2025), and $352000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 286,000.00 |
| Dec 31, 2025 | 286,000.00 |
| Sep 30, 2025 | 282,000.00 |
| Sep 30, 2025 | 282,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Mar 31, 2025 | 432,000.00 |
| Mar 31, 2025 | 432,000.00 |
| Dec 31, 2024 | 432,000.00 |
| Dec 31, 2024 | 432,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Mar 31, 2024 | 402,000.00 |
| Mar 31, 2024 | 402,000.00 |
| Dec 31, 2023 | 396,000.00 |
| Dec 31, 2023 | 396,000.00 |
| Sep 30, 2023 | 389,000.00 |
| Sep 30, 2023 | 389,000.00 |